Influence of Cerebral Oedema in Intracerebral Haemorrhage
Consequences of Oedema on the Prognosis of InTraCerebral Haemorrhage
University Hospital, Lille
500 participants
Jun 4, 2021
INTERVENTIONAL
Conditions
Summary
In 2020, IntraCerebral Haemorraghe (ICH) remains the most devastating type of stroke. Besides stroke unit care, no specific treatment has been proven effective yet. Perihaematomal oedema (PHO) could be a promising therapeutic target. However, the mechanisms, the natural history as well as the clinical impact of this PHO remain unclear. The COPITCH study has been designed to answer these questions
Eligibility
Inclusion Criteria4
- With a spontaneous ICH, i.e. non traumatic
- Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well will be considered as stroke onset
- Patient insured under the French social security
- Consent form signed
Exclusion Criteria9
- Pure intraventricular haemorrhages
- "secondary" ICH: ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma or tumour; haemorrhagic transformation within an infarct
- Pre-admission modified Rankin score of 4 or 5
- Life expectancy of less than 1 year related to comorbidities (end stage cancer, end stage organ failure)
- Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done)
- Adults who are deprived of their liberty by judicial or administrative decision
- Referral from other hospitals
- Contra-indication to MRI : claustrophobia, ocular metallic foreign bodies (accidental or other) or in a risk area (nervous or vascular system);irremovable implanted medical device (pacemaker, neurostimulator, cochlear implants and others);metallic heart valve (mainly old heart valves) or vascular clips previously implanted on cranial aneurysms; gadolinium allergy
- No consent form
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Brain MRI will include differents sequences.
Biological biomarkers will include a set of systemic inflammatory markers
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04621357